TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.

Company profile
Ticker
TXMD
Exchange
Website
CEO
Robert Finizio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO
SEC CIK
Corporate docs
Subsidiaries
VitaMedMD, LLC • BocagreenMD, Inc. • VitaCare Prescription Services, Inc. ...
IRS number
870233535
TXMD stock data
News

TherapeuticsMD Earnings Preview
12 Aug 22
$15 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying
2 Aug 22
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
2 Aug 22
U.S. Stocks Turn Negative; Dow Drops Over 100 Points
1 Aug 22
12 Health Care Stocks Moving In Monday's Intraday Session
1 Aug 22
Press releases
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
8 Aug 22
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
8 Aug 22
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
1 Aug 22
TherapeuticsMD Announces Expiration of Tender Offer
13 Jul 22
EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer
6 Jul 22
Analyst ratings and price targets
Investment data
Securities sold
Number of investors
Calendar
16 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.38M | 30.38M | 30.38M | 30.38M | 30.38M | 30.38M |
Cash burn (monthly) | 11.58M | 8.94M | 16.34M | 15.17M | 9.84M | 11.15M |
Cash used (since last report) | 51.14M | 39.47M | 72.16M | 67M | 43.47M | 49.26M |
Cash remaining | -20.75M | -9.08M | -41.78M | -36.62M | -13.08M | -18.87M |
Runway (months of cash) | -1.8 | -1.0 | -2.6 | -2.4 | -1.3 | -1.7 |
My content
My notes
No notes yet
My annotations
No annotations yet
Community content
Community notes
No notes yet
Community annotations
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jul 22 | Rubric Capital Management | Series A Preferred Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 822.21 | 15,000 | 12.33M | 15,000 |
29 Jul 22 | Rubric Capital Management | Common Stock, par value $0.001 per share ("Common Stock") | Buy | Acquire P | Yes | No | 4.72 | 565,000 | 2.67M | 1,721,953 |
18 Jul 22 | Rubric Capital Management | Common Stock | Buy | Acquire P | Yes | No | 6.03 | 17,688 | 106.66K | 1,156,953 |
15 Jul 22 | Rubric Capital Management | Common Stock, par value $0.001 per share ("Common Stock") | Buy | Acquire P | Yes | No | 5.56 | 64,892 | 360.8K | 1,139,265 |
31 Mar 22 | Hugh O'Dowd | Performance Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 2,125,000 | 0 | 2,125,000 |
31 Mar 22 | Marlan D Walker | Performance Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 260,000 | 0 | 260,000 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 125 |
Opened positions | 16 |
Closed positions | 25 |
Increased positions | 27 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 65.7M |
Total shares | 138.37M |
Total puts | 170.2K |
Total calls | 295.3K |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 24.44M | $9.29M |
Flynn James E | 20.66M | $23.14M |
Vanguard | 17.45M | $6.63M |
Smith Robert J | 11.35M | $0 |
STT State Street | 7.26M | $2.76M |
MS Morgan Stanley | 7.26M | $2.76M |
Geode Capital Management | 6.63M | $2.52M |
C WorldWide Group Holding A/S | 6.19M | $2.35M |
Rubric Capital Management | 5.34M | $2.03M |
NTRS Northern Trust | 3.54M | $1.34M |
Financial report summary
?Competition
Mylan • Pfizer • Amag Pharmaceuticals • Agile Therapeutics • Allergan • Mylan II B.V. • Amneal PharmaceuticalsRisks
- Our financial condition and results of operations for 2020 and 2021 were, and our financial condition and results of operations for 2022 and beyond may be, adversely affected by the ongoing COVID-19 pandemic.
- We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.
- Our level of indebtedness and the terms of the Financing Agreement, which matures in June 2022, raises substantial doubt about our ability to continue as a going concern.
- We may not recognize any anticipated benefits of the proposed disposition of vitaCare or any other divestitures we may pursue in the future.
- We may not be able to realize the expected savings from our cost savings initiatives.
- We have experienced significant turnover in our top executives, and our business could be adversely affected by these and other transitions in our senior management team.
- We currently derive all revenue from sales or licenses of our women’s healthcare products, and our failure to maintain or increase sales of these products could have an adverse effect on our business, financial condition, results of operations, and growth prospects.
- The commercial success of our existing products and other pharmaceutical products that we may develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payers.
- We may not be able to complete the commercialization of our pharmaceutical products and development of future product candidates if we fail to obtain additional financing.
- Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability.
- We are subject to extensive and costly government regulation.
- Future legislation or regulations may adversely affect reimbursement from government healthcare programs and third-party payers.
- Even after the approval of IMVEXXY, BIJUVA, and ANNOVERA, and even if we obtain regulatory approval for other pharmaceutical product candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.
- Recent government enforcement has targeted pharmaceutical companies for violations of fraud, abuse and other laws.
- Licensing of intellectual property involves complex legal, business, and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or adversely affect our ability to develop and commercialize other products in the future.
- Our products face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.
- Failure to obtain regulatory approval outside the U.S. will prevent our licensees from marketing our hormone therapy pharmaceutical products in non-U.S. markets.
- Our success is tied to our distribution channels.
- We rely on third parties to conduct our R&D activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our pharmaceutical product candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.
- Our ability to utilize net operating loss carryforwards may be limited.
- Our operations are concentrated in Boca Raton, Florida and interruptions affecting us or our suppliers due to natural disasters, the COVID-19 pandemic, or other unforeseen events could adversely affect our operations.
- Any failure to adequately maintain a sales force will impede our growth.
- We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
- If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products and other products are not adequate, we may not be able to compete effectively in our market.
- We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.
- If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- Some provisions of our charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.
- Our business may be affected by unfavorable publicity or lack of consumer acceptance.
- Our success depends on how efficiently we respond to changing consumer preferences and demand.
- We may initiate product recalls or withdrawals or may be subject to regulatory enforcement actions that could negatively affect our business.
- Product liability lawsuits could divert our resources, result in substantial liabilities, and reduce the commercial potential of our products.
- If we use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.
- If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
- A failure to maintain optimal inventory levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.
- Delays in clinical trials are common for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval or commence or continue product sales.
- We may be required to suspend or discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our pharmaceutical product candidates.
- Our business may be impacted by new or changing tax laws or regulations and actions by federal, state, and/or local agencies, or how judicial authorities apply tax laws.
- We may not be able to maintain effective and efficient information systems or properly safeguard our information systems.
- Our failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
- Our employees and business partners may not appropriately secure and protect confidential information in their possession.
- Another party could develop competing pharmaceutical products and obtain FDA regulatory exclusivity in the U.S. before we do, potentially preventing our ability to commercialize our pharmaceutical products and other products in development.
- If we are sued for infringing intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or commercializing our pharmaceutical product candidates.
- If we are unable to protect the confidentiality of certain information, the value of our products and technology could be adversely affected.
- We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties with whom we have obligations of confidentiality.
- The market price of our common stock may be highly volatile, and you could lose all or part of your investment.
- If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
- Future sales and issuances of equity securities, convertible securities or other securities could result in additional dilution of the percentage ownership of holders of our common stock.
Management Discussion
- Our sales of ANNOVERA were $8.5 million for the first quarter of 2022, a decrease of $0.2 million, or 2.7%, compared to the first quarter of 2021. This decrease was primarily due to a 1.5% decrease in sales volume and a 1.3% decrease in the average sale price.
- Our sales of IMVEXXY were $7.0 million for each of the first quarter of 2022 and 2021. The quarter over quarter change was primarily attributable to a 2.0% decrease in the average sale price, which was partially offset by a 1.4% increase in sales volume.
- Our sales of BIJUVA were $2.6 million for the first quarter of 2022, an increase of $0.1 million, or 4.7%, compared to the first quarter of 2021. Included in our BIJUVA sales for the first quarter of 2022 was $0.7 million of sales made through the Theramex License
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
added, apparent, applied, apply, assume, ASU, automating, capacity, ceased, circulating, correspondingly, critical, CRL, curtail, customary, declined, default, disease, divestiture, ease, effectuate, employment, exceeded, extinguishment, Facilitation, feedback, forecast, forward, fractional, Instruction, Interbank, intermittent, key, kind, labor, London, maximum, meantime, merge, par, penalty, PIK, platform, preceding, prospectively, prove, PSU, ramping, ratio, readily, realize, realized, reassessment, remeasurement, renewable, repay, resigned, retention, Scope, sheet, smaller, Topic, unchanged, unfavorable, waivable, waived, yield
Removed:
absorption, accept, acceptance, accrual, accurately, achieve, acquisition, actively, adjust, administered, administration, affordable, aggregate, aid, alternative, amenorrhea, Amneal, androgen, announced, annum, applicator, approach, asset, ATM, bad, behalf, beneficial, bind, birth, bleeding, blood, body, borrowed, borrowing, broker, calculate, Carrol, case, channel, characterized, chemical, chemistry, Chew, choice, chosen, claimed, classified, clinically, closed, closely, collected, collection, comfortable, competing, competitive, component, concentration, conducted, consented, consist, consistent, constrain, constrained, consumer, contracted, convenient, corporate, costly, cumulative, customer, cutting, dating, decide, declared, deducted, deducting, delinquency, delinquent, delivery, demonstrated, desire, determine, determining, developing, dietary, digitally, director, discount, dispensed, disposition, Dispute, disputed, distributor, doctor, dollar, domestic, dose, dosing, duty, earned, easy, education, efficacy, effort, elastomer, empowering, endpoint, entitled, entity, establish, evidence, exclude, execution, exercised, exist, existed, expired, extend, extensive, facility, familiar, favor, FDRR, fertility, fiscal, floor, Florida, FOLMAX, Food, Formal, framework, frequency, funding, glucocorticoid, gluten, government, growth, guarantee, highest, history, hold, holder, home, hormonal, impairment, individual, influence, ingredient, initial, insert, inserted, insertion, investment, invoice, issue, issuer, IUD, kosher, laboratory, level, light, line, list, loan, low, loyalty, macroeconomic, magnitude, maintained, manage, marketed, marketplace, maximize, meaningful, mechanism, menstruation, method, mg, minimize, molecular, monitored, Multivitamin, mutually, naturally, negatively, newly, November, objective, offer, office, oil, onboarded, onboarding, opportunity, option, original, outset, outsourced, overnight, override, owing, paper, patented, patient, peanut, Pearl, penetrate, percentage, perception, performing, personnel, pharmacological, pocket, point, policy, portion, positioned, positively, postmenopausal, potent, power, preclude, prescribe, preserve, pressure, prevailing, pricing, prime, procedure, produced, profile, progestin, program, project, promised, prompt, proper, proprietary, protect, protection, pursue, put, quality, reach, rebate, recognition, recognize, recover, reflecting, refund, regimen, registration, regular, reimburse, relating, release, relevance, reliance, remining, removed, repaid, REPLENISH, represent, representing, resold, resolution, resolved, respond, responsible, restrict, restrictive, return, returned, reversal, review, Rx, sample, satisfaction, satisfied, scheduled, sensitivity, settled, settlement, shelf, shipped, short, shown, side, significantly, silicone, size, small, softgel, specific, stated, stayed, steady, strong, structure, submission, sugar, supplement, supportable, supported, susceptible, sustained, systemic, telehealth, therapeutic, titled, trading, transferring, trial, True, ultimately, uncollectible, underway, underwriting, unique, unit, unsalable, unsecured, usage, user, utilizing, vagina, variable, vegan, vested, visibility, vitaTrue, vitro, vivo, volatility, WAC, week, weight, wholesaler, withdrew, woman, working, write, written
Financial reports
Current reports
8-K
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
1 Aug 22
8-K
Entry into a Material Definitive Agreement
29 Jul 22
8-K
Entry into a Material Definitive Agreement
28 Jul 22
8-K
Entry into a Material Definitive Agreement
25 Jul 22
8-K
Entry into a Material Definitive Agreement
14 Jul 22
8-K/A
Amendments to Articles of Incorporation or Bylaws
6 Jun 22
8-K
Entry into a Material Definitive Agreement
3 Jun 22
8-K
TherapeuticsMD and EW Healthcare Partners
31 May 22
8-K
Regulation FD Disclosure
20 May 22
8-K
TherapeuticsMD Announces First Quarter 2022 Financial Results
16 May 22
Registration and prospectus
SC 14D9/A
Tender offer solicitation (amended)
13 Jul 22
SC TO-T/A
Third party tender offer statement (amended)
13 Jul 22
SC 14D9/A
Tender offer solicitation (amended)
6 Jul 22
SC TO-T/A
Third party tender offer statement (amended)
6 Jul 22
SC 14D9/A
Tender offer solicitation (amended)
28 Jun 22
SC TO-T/A
Third party tender offer statement (amended)
23 Jun 22
SC 14D9
Tender offer solicitation
10 Jun 22
SC TO-T
Third party tender offer statement
6 Jun 22
SC TO-C
Information about tender offer
31 May 22
SC14D9C
Written communication relating to third party tender offer
31 May 22
Proxies
DEFA14A
Additional proxy soliciting materials
21 May 21
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEFA14A
Additional proxy soliciting materials
4 May 20
PRER14A
Preliminary revised proxy
22 Apr 20
PRE 14A
Preliminary proxy
13 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEF 14A
Definitive proxy
29 Apr 19
Other
EFFECT
Notice of effectiveness
6 May 20
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
20 Aug 18
UPLOAD
Letter from SEC
5 Feb 17
CORRESP
Correspondence with SEC
30 Jan 17
UPLOAD
Letter from SEC
24 Jan 17
CORRESP
Correspondence with SEC
28 Dec 16
UPLOAD
Letter from SEC
14 Dec 16
EFFECT
Notice of effectiveness
16 Nov 15
Ownership
SC 13D
TherapeuticsMD / Rubric Capital Management ownership change
8 Aug 22
4
TherapeuticsMD / David Efraim Rosen ownership change
1 Aug 22
4
TherapeuticsMD / David Efraim Rosen ownership change
19 Jul 22
3
TherapeuticsMD / David Efraim Rosen ownership change
19 Jul 22
SC 13G/A
TherapeuticsMD / BlackRock ownership change
8 Jul 22
SC 13G
TherapeuticsMD / Beryl Capital Management ownership change
3 Jun 22
4
TherapeuticsMD / Marlan D Walker ownership change
31 Mar 22
4
TherapeuticsMD / Hugh O'Dowd ownership change
31 Mar 22
4
TherapeuticsMD / Mark A Glickman ownership change
31 Mar 22
4
TherapeuticsMD / Michael C Donegan ownership change
31 Mar 22
Patents
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
7 Jun 22
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
19 Apr 22
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
8 Mar 22
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
Utility
Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods
17 Feb 22
The invention described herein relates to pharmaceutical compositions that are capable of delivering active pharmaceutical ingredients, such as estrogens, to the vagina and vagina-associated tissues and related methods of making and using such compositions (e.g., in the treatment of disease).
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
15 Feb 22
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
Transcripts
2022 Q1
Earnings call transcript
17 May 22
2021 Q4
Earnings call transcript
10 Mar 22
2021 Q3
Earnings call transcript
11 Nov 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
9 Nov 20
2020 Q2
Earnings call transcript
7 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
20 Feb 20
Reddit threads
Daily Discussion Thread - August 12th, 2022
12 Aug 22
$MNMD 1:15 Reverse Split - Good News?!
9 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
YOLO Stocks You Love for No Good Reason
4 Aug 22
Daily Discussion Thread - August 3rd, 2022
3 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
I chose Diamond Hands to the very end🤪
23 Jul 22
(7/13) Wednesday's Pre-Market Stock Movers & News
13 Jul 22
(7/6) Wednesday's Pre-Market Stock Movers & News
6 Jul 22